Market Overview:
The global chronic lung diseases treatment market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of chronic lung diseases, rising awareness about available treatments, and technological advancements in the field of chronic lung diseases treatment. The global chronic lung diseases treatment market is segmented by type into injection, capsule, tablet, and other. The injection segment accounted for the largest share of the global market in 2017 owing to its high efficacy and ease of use. By application, the bronchopulmonary dysplasia (BPD) segment accounted for the largest share of the global market in 2017 owing to its high prevalence among premature infants. The asthma segment is expected to grow at a highest CAGR during forecast period due to increasing incidence rates globally.
Product Definition:
Chronic Lung Diseases Treatment is the medical treatment of chronic lung diseases. The importance of Chronic Lung Diseases Treatment is that it can help improve a person's quality of life and extend their life expectancy.
Injection:
Injection is a medication used to treat chronic obstructive pulmonary disease (COPD) and asthma. The medicine is injected into the lungs through the vein. It works by opening airways and reducing swelling of lung tissues, making it easier to breathe. Inhaled medicines are not usually effective for people with severe COPD or emphysema as they do not reach high enough concentrations in the lungs to improve symptoms.
Capsule:
Capsule is a device used to deliver medicine to the target organ or tissue. It is a sachet-like delivery system made up of inert material (plastic, paper, and others) that contains the drug along with an opening at one end through which the contents can be administered. The other end consists of a septum that seals after administration thus preventing re-contamination of the medication and maintaining purity levels.
Application Insights:
Chronic lung diseases treatment market by application is segmented into bronchopulmonary dysplasia, asthma, COPD and pulmonary fibrosis. Among these disorders, chronic bronchitis accounted for the largest share in 2017 owing to its increasing prevalence and incidence rates. According to a research study published in NCBI in 2018, it was estimated that around 1-2% of children suffer from chronic bronchitis every year across the globe.
The COPD segment is expected to grow at a lucrative rate during the forecast period due to its high prevalence and incidence rates coupled with rising geriatric population across the globe. For instance, as per data published by Global Burden of Disease Study 2016 Chronic Obstructive Pulmonary Disease (COPD) caused by smoking or other causes was prevalent among approximately 65 million people globally which increased their mortality rate by 33%.
Regional Analysis:
North America dominated the global chronic lung diseases treatment market in 2017. This can be attributed to the presence of a large number of key players, high adoption rate for innovative products, and favorable reimbursement policies. In addition, increasing prevalence of chronic lung diseases is expected to drive regional growth over the forecast period. For instance, as per American Lung Association (ALA), in 2016 around 20 million people suffer from COPD in U.S.
Growth Factors:
- Increasing prevalence of chronic lung diseases
- Growing awareness about the available treatment options for chronic lung diseases
- Rising demand for better and more effective treatments for chronic lung diseases
- Technological advancements in the field of chronic lung diseases treatment 5. increasing funding for research and development in the field of chronic lung disease treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Lung Diseases Treatment Market Research Report
By Type
Injection, Capsule, Tablet, Other
By Application
Bronchopulmonary Dysplasia, Asthma, COPD, Pulmonary Fibrosis
By Companies
Boehringer Ingelheim, Novartis, Roche, Astellas Pharma, Dr. Reddy’s Laboratories, GlaxoSmithKline, AstraZeneca, Sanofi, Teva Pharmaceuticals, Asmacure Ltée
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Lung Diseases Treatment Market Report Segments:
The global Chronic Lung Diseases Treatment market is segmented on the basis of:
Types
Injection, Capsule, Tablet, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bronchopulmonary Dysplasia, Asthma, COPD, Pulmonary Fibrosis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Novartis
- Roche
- Astellas Pharma
- Dr. Reddy’s Laboratories
- GlaxoSmithKline
- AstraZeneca
- Sanofi
- Teva Pharmaceuticals
- Asmacure Ltée
Highlights of The Chronic Lung Diseases Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Capsule
- Tablet
- Other
- By Application:
- Bronchopulmonary Dysplasia
- Asthma
- COPD
- Pulmonary Fibrosis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Lung Diseases Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic lung diseases treatment is a combination of therapies that aim to improve the patient's quality of life and extend their lifespan. Treatment may include medications, surgery, and other treatments.
Some of the key players operating in the chronic lung diseases treatment market are Boehringer Ingelheim, Novartis, Roche, Astellas Pharma, Dr. Reddy’s Laboratories, GlaxoSmithKline, AstraZeneca, Sanofi, Teva Pharmaceuticals, Asmacure Lt©e.
The chronic lung diseases treatment market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Lung Diseases Treatment Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Chronic Lung Diseases Treatment Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Chronic Lung Diseases Treatment Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Chronic Lung Diseases Treatment Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Chronic Lung Diseases Treatment Market Size & Forecast, 2020-2028 4.5.1 Chronic Lung Diseases Treatment Market Size and Y-o-Y Growth 4.5.2 Chronic Lung Diseases Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Capsule
5.2.3 Tablet
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Bronchopulmonary Dysplasia
6.2.2 Asthma
6.2.3 COPD
6.2.4 Pulmonary Fibrosis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Lung Diseases Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Lung Diseases Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Capsule
9.6.3 Tablet
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Bronchopulmonary Dysplasia
9.10.2 Asthma
9.10.3 COPD
9.10.4 Pulmonary Fibrosis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Capsule
10.6.3 Tablet
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Bronchopulmonary Dysplasia
10.10.2 Asthma
10.10.3 COPD
10.10.4 Pulmonary Fibrosis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Capsule
11.6.3 Tablet
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Bronchopulmonary Dysplasia
11.10.2 Asthma
11.10.3 COPD
11.10.4 Pulmonary Fibrosis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Capsule
12.6.3 Tablet
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Bronchopulmonary Dysplasia
12.10.2 Asthma
12.10.3 COPD
12.10.4 Pulmonary Fibrosis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Capsule
13.6.3 Tablet
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Bronchopulmonary Dysplasia
13.10.2 Asthma
13.10.3 COPD
13.10.4 Pulmonary Fibrosis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Lung Diseases Treatment Market: Competitive Dashboard
14.2 Global Chronic Lung Diseases Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim
14.3.2 Novartis
14.3.3 Roche
14.3.4 Astellas Pharma
14.3.5 Dr. Reddy’s Laboratories
14.3.6 GlaxoSmithKline
14.3.7 AstraZeneca
14.3.8 Sanofi
14.3.9 Teva Pharmaceuticals
14.3.10 Asmacure Ltée